Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors

In recent years, immune checkpoint inhibitors (ICIs) have become the standard treatment option for tumors. With the widespread application of ICIs, immune-related adverse events (irAEs) have gradually attracted the attention of researchers. Owing to the characteristics of ICIs, irAEs can affect each...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Xue-lin, Chen, Wei-yong, Zhang, Guang-yan, Ke, Hua, Yang, Qiu-hong, Li, Xiao-bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606686/
https://www.ncbi.nlm.nih.gov/pubmed/34819857
http://dx.doi.org/10.3389/fphar.2021.747075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606686/
https://www.ncbi.nlm.nih.gov/pubmed/34819857
http://dx.doi.org/10.3389/fphar.2021.747075

Ejemplares similares